Endo Paget Biochemical Relapse Monitoring

---
name: endo-paget-biochemical-relapse-monitoring
description: The guideline recommends using biochemical follow-up as a more objective indicator of relapse than symptoms in patients with increased bone turnover after treatment for Paget’s disease. Trigger phrases include monitoring for disease recurrence after bisphosphonate therapy, evaluating rising bone turnover markers, and assessing asymptomatic patients.
---

# Use biochemical follow-up to detect relapse

## STEP 1 — Gather Information
Identify patients with a history of treated Paget’s disease who have increased bone turnover (elevated serum total alkaline phosphatase [ALP], procollagen type 1 N‑terminal propeptide [P1NP], bone‑specific ALP [BSAP], C‑telopeptide [CTx], or N‑telopeptide [NTx]). Obtain the most recent baseline marker level recorded after treatment and note the assay used. Review liver function tests if ALP is the primary marker to exclude hepatic contribution.

## STEP 2 — Rule In / Rule Out
Determine whether the current marker level shows a biologically significant increase compared with the post‑treatment nadir or baseline. Use the least significant change (LSC) for the specific assay: a rise exceeding the LSC suggests true biochemical relapse; a change within the LSC or a stable/decreasing level argues against relapse.

## STEP 3 — Classify or Stratify
If the marker rise exceeds the LSC, classify as biochemical relapse and assess magnitude (e.g., mild: 1–2 × LSC; moderate: 2–3 × LSC; marked: >3 × LSC). If the change is within LSC or continues to decline, classify as no biochemical evidence of relapse and continue routine surveillance.

## STEP 4 — Decide
For confirmed biochemical relapse, consider retreatment with a potent bisphosphonate (e.g., a single 5 mg intravenous zoledronate dose) especially if the patient is at risk for complications. If no relapse is detected, maintain the current monitoring interval (1–2 years after zoledronate, 6–12 months after less potent agents) and repeat biomarker testing at the next scheduled visit.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on symptoms such as bone pain, as it may reflect degenerative joint disease rather than Paget’s activity. Avoid interpreting isolated ALP elevations without confirming liver function normality. Recognize assay variability and biological fluctuation; a single borderline rise should be confirmed with a repeat test before acting. Do not obtain routine radionuclide bone scans solely based on marker changes unless clinical suspicion is high.

## Concrete Clinical Example
A 68‑year‑old woman treated 18 months ago with intravenous zoledronate for symptomatic pelvic Paget’s disease had a post‑treatment ALP of 55 U/L. She returns asymptomatic; repeat ALP is 92 U/L. The assay’s LSC is 30 U/L, so the rise exceeds LSC, indicating biochemical relapse. She receives a second 5 mg zoledronate infusion and is scheduled for ALP re‑check in 6 months.

**Source:** Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910